PE20180228A1 - Mezcla de acidos carboxilicos para tratar pacientes con insuficiencia renal - Google Patents

Mezcla de acidos carboxilicos para tratar pacientes con insuficiencia renal

Info

Publication number
PE20180228A1
PE20180228A1 PE2017001076A PE2017001076A PE20180228A1 PE 20180228 A1 PE20180228 A1 PE 20180228A1 PE 2017001076 A PE2017001076 A PE 2017001076A PE 2017001076 A PE2017001076 A PE 2017001076A PE 20180228 A1 PE20180228 A1 PE 20180228A1
Authority
PE
Peru
Prior art keywords
acid
treatment
patients
renal
transamination
Prior art date
Application number
PE2017001076A
Other languages
English (en)
Inventor
Miramontes Jorge Antonio Hernandez
Villanueva Jorge Alberto Hernandez
Original Assignee
Miramontes Jorge Antonio Hernandez
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=56234463&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20180228(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Miramontes Jorge Antonio Hernandez filed Critical Miramontes Jorge Antonio Hernandez
Publication of PE20180228A1 publication Critical patent/PE20180228A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/15—Vitamins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/16—Inorganic salts, minerals or trace elements
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A61K31/10—Sulfides; Sulfoxides; Sulfones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A61K31/51—Thiamines, e.g. vitamin B1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7135—Compounds containing heavy metals
    • A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A61K33/10—Carbonates; Bicarbonates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/26—Iron; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
    • C07C55/02—Dicarboxylic acids
    • C07C55/10—Succinic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
    • C07C55/02—Dicarboxylic acids
    • C07C55/20—Sebacic acid
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nutrition Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Physiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

Referido a una mezcla de acidos carboxilicos: acido citrico, acido succinico, acido fumarico y acido malico en combinacion con bicarbonato de sodio, calcio y lacta to de calcio. Este producto es benefico para disminuir los valores sericos de urea y de amonio serico, a la vez que por transaminacion del oxalacetato formado via succinato, fumarato y malato, promueve la biosintesis de aminoacidos no esenciales; por transaminacion del alfa ceto glutarato formado via citrato, genera acido glutamico y los aminoacidos relacionados al mismo como glutamina. Este tratamiento previene, preserva e inclusive mejora la funcion renal. En otros pacientes retarda el deterioro de la funcion renal y la imperiosa necesidad del tratamiento renal sustitutivo. Dicho producto se utiliza preferentemente via oral o tambien via intravenosa, en el tratamiento de pacientes con insuficiencia renal cronica, hiperamonemia o condiciones humanas que cursen con balance nitrogenado negativo. Tambien se utiliza como tratamiento complementario al tratamiento renal sustitutivo para mejorar la calidad de vida del paciente y mejorar los parametros laboratoriales.
PE2017001076A 2015-03-20 2015-11-04 Mezcla de acidos carboxilicos para tratar pacientes con insuficiencia renal PE20180228A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
MX2015003641A MX357998B (es) 2015-03-20 2015-03-20 Una mezcla de acidos carboxilicos, especificamente acido citrico, acido succinico, acido fumarico y acido malico para el tratamiento de pacientes con insuficiencia renal cronica, insuficiencia renal aguda, hepatopatias agudas o cronicas que cursen con hiperamonemia, enfermedades congenitas con alteraciones enzimaticas en el ciclo de la urea, asi como condiciones clínicas que cursen con balance nitrogenado negativo.

Publications (1)

Publication Number Publication Date
PE20180228A1 true PE20180228A1 (es) 2018-01-31

Family

ID=56234463

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2017001076A PE20180228A1 (es) 2015-03-20 2015-11-04 Mezcla de acidos carboxilicos para tratar pacientes con insuficiencia renal

Country Status (26)

Country Link
US (2) US10688068B2 (es)
EP (1) EP3219315B1 (es)
JP (1) JP6771191B2 (es)
KR (1) KR102057555B1 (es)
CN (1) CN108024981B (es)
AU (1) AU2015387986B2 (es)
BR (1) BR112017017189A2 (es)
CA (1) CA2972889C (es)
CL (1) CL2017001262A1 (es)
CO (1) CO2017007046A2 (es)
CR (1) CR20170320A (es)
DO (1) DOP2017000161A (es)
EA (1) EA036702B1 (es)
EC (1) ECSP17056559A (es)
ES (1) ES2850998T3 (es)
GT (1) GT201700149A (es)
HK (1) HK1249426A1 (es)
IL (1) IL253480B (es)
MX (1) MX357998B (es)
MY (1) MY173111A (es)
NZ (1) NZ733186A (es)
PE (1) PE20180228A1 (es)
PH (1) PH12017501157B1 (es)
SG (1) SG11201705163XA (es)
TN (1) TN2017000257A1 (es)
WO (1) WO2016153331A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018193648A1 (ja) * 2017-04-18 2018-10-25 国立大学法人東北大学 アルカリ性化剤による血液浄化
JP7219898B2 (ja) * 2017-04-18 2023-02-09 国立大学法人東北大学 アルカリ性化剤による血液浄化
IT201700087359A1 (it) * 2017-07-28 2019-01-28 Professional Dietetics Spa Composizioni comprendenti amino acidi per l'uso nel trattamento di malattie associate a disfunzione mitocondriale
IT201700087376A1 (it) 2017-07-28 2019-01-28 Professional Dietetics Spa Composizioni comprendenti amino acidi per l'uso nel trattamento di malattie associate a disfunzione mitocondriale
WO2020080499A1 (ja) * 2018-10-17 2020-04-23 国立大学法人東北大学 新規医薬組成物
CN109125310A (zh) * 2018-11-06 2019-01-04 河北工业大学 琥珀酸在抑制Kv10.1离子通道活性中的应用和药物
EP3976559A4 (en) 2019-05-30 2023-06-21 Koch Agronomic Services, LLC FOLIAR SOLUTIONS OF MICRONUTRIENTS
US11666548B2 (en) * 2020-06-05 2023-06-06 Baxter International Inc. Parenteral nutrition formulation
CN115414383A (zh) * 2022-10-14 2022-12-02 青岛普瑞森医药科技有限公司 血液透析浓缩液及其制备方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5475031A (en) * 1993-09-03 1995-12-12 Livingston; William H. Discovery of a valuable property for succinic acid and other intermediary metabolites
US5500232A (en) * 1994-10-06 1996-03-19 Bristol-Myers Squibb Company Calcium fortified beverages
US6488961B1 (en) * 1996-09-20 2002-12-03 Ethypharm, Inc. Effervescent granules and methods for their preparation
EP0938849A1 (en) 1998-02-18 1999-09-01 Quest International B.V. A composition with a fresh, fruit like taste
US6288116B1 (en) * 1998-05-13 2001-09-11 Novartis Nutrition Ag Method of administration of a nutritional product to a person having renal failure
AU7032700A (en) * 1999-10-12 2001-04-23 Meiji Seika Kaisha Ltd. Low potassium juice, method for producing thereof and food containing the same
AU2002211770A1 (en) * 2000-10-16 2002-04-29 Pepsico, Inc. Calcium-supplemented beverages and method of making same
US20030211204A1 (en) * 2002-05-10 2003-11-13 Fields Christine C. Method of preparing beverages and beverage concentrates nutritionally supplemented with minerals
US20090186127A1 (en) * 2004-12-15 2009-07-23 Krumhar Kim C Energy drink compositions
BRPI0602825A2 (pt) * 2006-06-23 2012-04-24 Rhodia Br Ltda formulação de pó efervescente auto-refrigerante para bebidas e uso de formulação em pó efervescente
US20080058421A1 (en) 2006-09-05 2008-03-06 John Alex Lopes Compositions for cleaning and disinfecting nasal tract and sinus cavity
CN101568334A (zh) * 2006-12-12 2009-10-28 味之素株式会社 铁代谢改善剂
JP5592609B2 (ja) * 2006-12-12 2014-09-17 エイワイファーマ株式会社 鉄代謝改善剤
US20080226799A1 (en) * 2007-03-14 2008-09-18 Concentrate Manufacturing Company Of Ireland Diet Cola Beverages
BRPI0816066A2 (pt) * 2007-08-31 2017-05-02 C B Fleet Company Incorporated método de prevenção de nefrocalcinose
NZ595867A (en) * 2009-05-15 2015-05-29 Biocepta Corp Compositions suitable for the topical treatment of fungal infections of the skin and nails
NL2009407C2 (en) 2012-09-03 2014-03-04 Dutch Renewable Energy B V Antimicrobial composition.

Also Published As

Publication number Publication date
GT201700149A (es) 2018-10-25
US20180000764A1 (en) 2018-01-04
EA036702B1 (ru) 2020-12-09
CA2972889C (en) 2019-04-23
MY173111A (en) 2019-12-27
JP6771191B2 (ja) 2020-10-21
CO2017007046A2 (es) 2018-01-05
IL253480A0 (en) 2017-09-28
PH12017501157A1 (en) 2017-11-27
US10688068B2 (en) 2020-06-23
SG11201705163XA (en) 2017-07-28
NZ733186A (en) 2018-09-28
JP2018505191A (ja) 2018-02-22
EP3219315A1 (en) 2017-09-20
AU2015387986A1 (en) 2017-07-13
EP3219315A4 (en) 2017-12-06
IL253480B (en) 2020-05-31
ECSP17056559A (es) 2017-10-31
DOP2017000161A (es) 2017-08-31
BR112017017189A2 (pt) 2018-04-03
CN108024981A (zh) 2018-05-11
CN108024981B (zh) 2021-07-20
EP3219315B1 (en) 2020-09-02
KR102057555B1 (ko) 2019-12-19
EA201700339A1 (ru) 2018-02-28
MX357998B (es) 2018-07-11
HK1249426A1 (zh) 2018-11-02
ES2850998T3 (es) 2021-09-02
WO2016153331A1 (es) 2016-09-29
US20200138755A1 (en) 2020-05-07
CR20170320A (es) 2017-08-14
TN2017000257A1 (en) 2018-10-19
KR20170104575A (ko) 2017-09-15
CL2017001262A1 (es) 2017-09-29
CA2972889A1 (en) 2016-09-29
PH12017501157B1 (en) 2017-11-27
AU2015387986B2 (en) 2018-12-20
MX2015003641A (es) 2016-04-08

Similar Documents

Publication Publication Date Title
PE20180228A1 (es) Mezcla de acidos carboxilicos para tratar pacientes con insuficiencia renal
PH12013502027A1 (en) Nutritional compositions having alpha-hica and alpha-ketoglutarate
EA201390934A1 (ru) Композиции и способы модулирования fxr
NZ607189A (en) Materials and methods for improving gastrointestinal function
EA201591050A1 (ru) Имидазопиридиновые соединения
CY1116320T1 (el) ΣΥΣΤΗΜΑ ΕΓΧΥΣΗΣ ΠΟΛΤΟΥ ΜΙΚΡΟΝΙΖΕ CaCO3 ΓΙΑ ΤΗΝ ΕΠΑΝΑΜΕΤΑΛΛΙΚΟΠΟΙΗΣΗ ΤΟΥ ΑΦΑΛΑΤΩΜΕΝΟΥ ΚΑΙ ΤΟΥ ΓΛΥΚΟΥ ΝΕΡΟΥ
EA200802095A1 (ru) ТВЕРДЫЕ ПРИНИМАЕМЫЕ ВНУТРЬ ЛЕКАРСТВЕННЫЕ КОМПОЗИЦИИ НА ОСНОВЕ S-АДЕНОЗИЛМЕТИОНИНА (SAMe) И/ИЛИ НИКОТИНАМИДАДЕНИНДИНУКЛЕОТИДА (NADH) И СПОСОБ ИХ ПОЛУЧЕНИЯ
DK1853248T3 (da) Anvendelse af salte, additionsforbindelser og kompleksforbindelser af quanidinoeddikesyre
EP3949973A3 (en) Compositions and methods for treating depression
EA201792597A2 (ru) Производные глутаримидов, их применение, фармацевтическая композиция на их основе, способы их получения
EA202091396A1 (ru) Композиции и способы лечения метаболических состояний
CY1123877T1 (el) Μορφες στερεας καταστασης αλατων νιλοτινιμπης
JP2009515953A5 (es)
TN2015000150A1 (en) Stable injectable composition containing diclofenac and thiocolchicoside
UY36366A (es) Métodos para inhibir la infección durante la cicatrización con composiciones tópicas que incluyen aminoácidos
PH12020551060A1 (en) Methods of treating chronic inflammatory diseases
MX2016014261A (es) Uso de acido 1,3-propandisulfonico o sales farmaceuticamente aceptables del mismo para el tratamiento de sarcoidosis.
EA201391034A1 (ru) Состав раствора аминокислот и его использование для лечения задержки внутриутробного развития плода (звур) или для парентерального питания сильно недоношенных новорожденных
JOP20220211A1 (ar) تركيبات صيدلانية من أملاح إستر كولين حمض ليبويك وطرق للمعالجة باستخدامها
Pedron Application of botulinum toxin associated with resective gingival surgery in the management of gummy smile
RU2012146985A (ru) Композиция для улучшения состояния при гипоальбуминемии
MX2016017336A (es) Uso de acido bisfosfonico y sus sales en la preparacion de composiciones utiles en el tratamiento de la osteoporosis.
RU2009119905A (ru) Способ получения препаратов для лечения анаплазмоза крупного рогатого скота
NZ764041A (en) Use of 1,3-propanedisulfonic acid or pharmaceutically acceptable salts thereof for the treatment of sarcoidosis
AR080322A1 (es) Una unidad de composicion farmaceutica de dosis oral que abarca levodopa, carbidopa y entacapone o sus sales. proceso de preparacion. metodo de tratamiento.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal